160 related articles for article (PubMed ID: 21902446)
1. Compliance, persistence, and switching patterns for ACE inhibitors and ARBs.
Vegter S; Nguyen NH; Visser ST; de Jong-van den Berg LT; Postma MJ; Boersma C
Am J Manag Care; 2011 Sep; 17(9):609-16. PubMed ID: 21902446
[TBL] [Abstract][Full Text] [Related]
2. Physician-specific variation in medication adherence among diabetes patients.
Sherman BW; Sekili A; Prakash ST; Rausch CA
Am J Manag Care; 2011 Nov; 17(11):729-36. PubMed ID: 22084892
[TBL] [Abstract][Full Text] [Related]
3. Reducing costs and improving hypertension management.
Stankus V; Hemmelgarn B; Campbell NR; Chen G; McAlister FA; Tsuyuki RT
Can J Clin Pharmacol; 2009; 16(1):e151-5. PubMed ID: 19193969
[TBL] [Abstract][Full Text] [Related]
4. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
5. Long-term persistence to mono and combination therapies with angiotensin converting enzymes and angiotensin II receptor blockers in Australia.
Gadzhanova S; Roughead EE; Bartlett LE
Eur J Clin Pharmacol; 2016 Jun; 72(6):765-71. PubMed ID: 26961086
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
7. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial.
Christian JB; Lapane KL; Hume AL; Eaton CB; Weinstock MA;
J Natl Cancer Inst; 2008 Sep; 100(17):1223-32. PubMed ID: 18728281
[TBL] [Abstract][Full Text] [Related]
8. Uptake of angiotensin II receptor blockers in the treatment of hypertension.
Greving JP; Denig P; van der Veen WJ; Beltman FW; Sturkenboom MC; de Zeeuw D; Haaijer-Ruskamp FM
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):461-6. PubMed ID: 15912393
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users.
de Jong HJ; Vandebriel RJ; Saldi SR; van Dijk L; van Loveren H; Cohen Tervaert JW; Klungel OH
Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):835-43. PubMed ID: 22674737
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
[TBL] [Abstract][Full Text] [Related]
11. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
13. Use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and lipid-lowering therapies among Rhode Islanders with diabetes enrolled in Medicare Part D plans in 2006 and 2007.
Kogut S; Caffrey A; Pezzullo L
Med Health R I; 2009 Nov; 92(11):373-6. PubMed ID: 19999898
[No Abstract] [Full Text] [Related]
14. Pharmacological treatment after acute myocardial infarction from 2001 to 2006: a survey in Italian primary care.
Filippi A; D'Ambrosio G; Giustini SE; Pecchioli S; Mazzaglia G; Cricelli C
J Cardiovasc Med (Hagerstown); 2009 Sep; 10(9):714-8. PubMed ID: 19465867
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive persistence and drug class.
Marentette MA; Gerth WC; Billings DK; Zarnke KB
Can J Cardiol; 2002 Jun; 18(6):649-56. PubMed ID: 12107422
[TBL] [Abstract][Full Text] [Related]
16. Parabolas of medication use and discontinuation after myocardial infarction--are we closing the treatment gap?
Hudson M; Richard H; Pilote L
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):773-85. PubMed ID: 17486661
[TBL] [Abstract][Full Text] [Related]
17. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.
Tsuchihashi-Makaya M; Furumoto T; Kinugawa S; Hamaguchi S; Goto K; Goto D; Yamada S; Yokoshiki H; Takeshita A; Tsutsui H;
Hypertens Res; 2010 Mar; 33(3):197-202. PubMed ID: 19960016
[TBL] [Abstract][Full Text] [Related]
18. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence.
Simpson E; Beck C; Richard H; Eisenberg MJ; Pilote L
Am Heart J; 2003 Mar; 145(3):438-44. PubMed ID: 12660666
[TBL] [Abstract][Full Text] [Related]
19. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.
Winkelmayer WC; Fischer MA; Schneeweiss S; Wang PS; Levin R; Avorn J
Am J Kidney Dis; 2005 Dec; 46(6):1080-7. PubMed ID: 16310574
[TBL] [Abstract][Full Text] [Related]
20. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
